Partial reprogramming by cyclical overexpression of Yamanaka factors improves pathological phenotypes of tauopathy mouse model of human Alzheimer's disease

Partial reprogramming induced by the controlled and cyclical overexpression of Yamanaka factors in the nervous system has so far succeeded in reversing some aging-associated phenotypes, such as improving memory function. These promising results suggest that partial reprogramming could be a potential...

Descripción completa

Detalles Bibliográficos
Autores: Antón-Fernández, Alejandro, Ruiz de Alegría, Álvaro, Mariscal-Casero, Ana, Roldán-Lázaro, Marta, Peinado-Cauchola, Rocío, Ávila, Jesús, Hernández Pérez, Félix
Tipo de recurso: artículo
Fecha de publicación:2025
País:España
Institución:Universidad Autónoma de Madrid
Repositorio:Biblos-e Archivo. Repositorio Institucional de la UAM
Idioma:inglés
OAI Identifier:oai:dnet:biblosearchi::88134e723bab0ad05809435aa20f6623
Acceso en línea:https://hdl.handle.net/10486/763500
https://dx.doi.org/10.1016/j.pneurobio.2025.102743
Access Level:acceso abierto
Palabra clave:Alzheimer
tau-P301S
transgenic mice
tau
H3K9me3
GFAP
Biología y Biomedicina / Biología
Descripción
Sumario:Partial reprogramming induced by the controlled and cyclical overexpression of Yamanaka factors in the nervous system has so far succeeded in reversing some aging-associated phenotypes, such as improving memory function. These promising results suggest that partial reprogramming could be a potential strategy to prevent or mitigate aging-related pathologies like tauopathies, including Alzheimer's disease. Here, we explore the potential of this strategy in addressing tauopathy development in the P301S mouse model. To achieve this, a new transgenic animal was created that can inducibly overexpress Yamanaka factors upon doxycycline administration and carries the Tau-P301S mutation, which leads to tauopathy development. The results of this study show a significant improvement in key pathological features of tauopathies in the hippocampus, including reversed tauopathy, alleviated reactive astrogliosis, age-related reduction of the H3K9me3 epigenetic marker, along with improved spatial memory, which has been described as deteriorated in this model. These findings reinforce the potential of partial reprogramming as a therapeutic strategy to combat brain pathologies associated with aging